Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathologic characterization of plasma cell neoplasms with IGH::CCND3.

American journal of clinical pathology·2026
Same author

Social Determinants of Health and End-of-Life Circumstances in a Quaternary Children's Hospital.

Journal of pain and symptom management·2026
Same author

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The American journal of surgical pathology·2026
Same author

NEAT1: a multifaceted long non-coding RNA in multiple myeloma.

Haematologica·2025
Same author

The impact of growth factor utilization on infection risk in patients receiving bispecific monoclonal antibodies.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2025
Same author

Induction Regimens in High-Risk Neuroblastoma: Systematic Review of Response Rates and Toxicities.

Cancer medicine·2025

Related Experiment Video

Updated: Apr 21, 2026

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

11.4K

Extramedullary Waldenström macroglobulinemia.

Ranjit Banwait1, Yosra Aljawai, Joseph Cappuccio

  • 1Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts.

American Journal of Hematology
|October 29, 2014
PubMed
Summary

Extramedullary disease (EMD) occurs in 4.4% of Waldenstrom Macroglobulinemia (WM) patients, often developing after therapy. This study details EMD characteristics, revealing pulmonary and central nervous system involvement, and provides survival data for this rare WM manifestation.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

10.6K

Related Experiment Videos

Last Updated: Apr 21, 2026

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
10:41

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Published on: March 29, 2017

11.4K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

10.6K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Waldenstrom Macroglobulinemia (WM) diagnosis relies on bone marrow B-cell neoplasm percentage and serum IgM paraprotein levels.
  • Extramedullary disease (EMD) in WM is infrequently assessed, and its diagnostic and prognostic significance remains unclear.

Purpose of the Study:

  • To characterize the clinical features, presentation, and outcomes of patients with extramedullary Waldenstrom Macroglobulinemia (WM).

Main Methods:

  • Retrospective analysis of 985 WM patients treated at a single academic center.
  • Assessment of EMD presence, sites of involvement, and correlation with patient survival.

Main Results:

  • EMD was identified in 4.4% of WM patients (43 individuals).
  • EMD manifested at diagnosis in 21% and post-therapy in 79% of cases.
  • Common EMD sites included pulmonary (30%), cerebrospinal fluid (23%), and soft tissue (21%).
  • The median 10-year overall survival for patients with EMD was 79%.

Conclusions:

  • Extramedullary disease is an uncommon but significant feature in Waldenstrom Macroglobulinemia.
  • Understanding EMD characteristics is crucial for comprehensive WM patient management.
  • Further research into the molecular underpinnings of EMD in WM is warranted.